X0306 4/A 2020-05-06 2020-05-07 0 0001679082 Myovant Sciences Ltd. MYOV 0001798550 Sumitomo Chemical Co., Ltd. 27-1, SHINKAWA 2-CHOME CHUO-KU, TOKYO M0 104-8260 JAPAN 0 0 1 0 0001446601 Dainippon Sumitomo Pharma Co Ltd 6-8 DOSHOMACHI 2-CHOME CHUO-KU, OSAKA M0 541-0045 JAPAN 0 0 1 0 0001798244 Sumitovant Biopharma Ltd. 11-12 ST. JAMES'S SQUARE SUITE 1 3RD FLOOR LONDON X0 SW1Y 4LB UNITED KINGDOM 0 0 1 0 Common Stock 2020-05-06 4 P 0 50000 12.2415 A 48247693 I See Footnote On May 7, 2020, the Reporting Persons filed a Form 4 disclosing the acquisition of 50,000 shares of Common Stock at an average stock price of $11.6893 (the "First Acquisition") and 50,000 shares of Common Stock at an average stock price of $12.2415 (the "Second Acquisition"). The transaction date reported in Box 2 for both the First Acquisition and the Second Acquisition was May 5, 2020. The transaction date for the Second Acquisition was incorrectly reported and should have been reported as May 6, 2020. This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020. The price reported in column 4 is the average stock price. Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Sumitomo Chemical Co., Ltd. By: /s/ Krunal Shah, as Attorney-in-Fact 2020-05-11 Sumitomo Dainippon Pharma Co., Ltd. By: Tsutomu Nakagawa, Senior Director, Global Corporate Strategy /s/ Tsutomu Nakagawa 2020-05-11 Sumitovant Biopharma Ltd. By: /s/ Krunal Shah, as Attorney-in-Fact 2020-05-11